Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK To Downplay Europe Because of Poor Innovation Support, Focuses On U.S. and Japan Instead

This article was originally published in The Pink Sheet Daily

Executive Summary

GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products

You may also be interested in...



Bayer Chief: Pharma’s Bad Rep Puts Europe Drug Business Model At Risk

Bayer‘s Chairman Marijn Dekkers says the pharma sector’s poor public reputation and consequent loss of faith in the industry risks destroying the European drug business model.

German Drug Report Could Mean More Pressure On Pharma Revenues

The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.

Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher

Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel